VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Cytokine1 who wrote (5765)	10/19/1998 11:00:00 AM
From: Mike McFarland	Read Replies (1) of 9719

Portfolio holding GZTC: Genzyme Transgenics Corporation Signs Twelfth Development Agreement for Transgenically-Produced Therapeutic Monoclonal Antibody biz.yahoo.com Upon commercialization of the antibody, Genzyme Transgenics will manufacture bulk product for sale in a market currently estimated to approach $600 million annually worldwide. Genzyme Transgenics will receive manufacturing fees and an undisclosed royalty on sales, resulting in potential revenues of about $35 million annually. The antibody is projected to enter phase III human clinical trials during 1999. (that's sweet) Rick--your the monoclonal antibody enthusiast, any feedback on this news release? GZTC has a market cap of a mere 70M. Price to future sales ratio looking awfully low as these things add up. -MM

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next